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AbstrAct
Objectives To identify and prioritise important research 
questions for miscarriage.
Design A priority setting partnership using prospective 
surveys and consensus meetings following methods 
advocated by the James Lind Alliance.
setting UK.
Participants Women and those affected by miscarriage 
working alongside healthcare professionals.
results In the initial survey, 1093 participants (932 
women who have experienced miscarriage, 8 partners, 
17 family members, friends or colleagues, 104 healthcare 
professionals and eight charitable organisations) submitted 
3279 questions. A review of existing literature identified 
a further 64. Non-questions were removed, and the 
remaining questions were categorised and summarised 
into 58 questions. In an interim electronic survey, 2122 
respondents chose their top 10 priorities from the 58 
summary questions. The 25 highest ranked in the survey 
were prioritised at a final face-to-face workshop. In 
summary, the top 10 priorities were ranked as follows: 
research into preventative treatment, emotional aspects 
in general, investigation, relevance of pre-existing 
medical conditions, emotional support as a treatment, 
importance of lifestyle factors, importance of genetic and 
chromosomal causes, preconception tests, investigation 
after different numbers of miscarriage and male causal 
factors.
conclusions These results should be the focus of 
future miscarriage research. Presently, studies are being 
conducted to address the top priority; however, many other 
priorities, especially psychological and emotional support, 
are less well researched areas. We hope our results will 
encourage both researchers and funders to focus on these 
priorities.
IntrODuctIOn
Miscarriage is defined as pregnancy loss from 
conception to 24 weeks’ gestation. Approx-
imately 15% of all clinically recognised 
pregnancies end this way.1 Most miscarriages 
occur in the first trimester, while only 1% 
occur after 12 weeks’ gestation.2 Recurrent 
miscarriage, defined as three or more consec-
utive pregnancy losses, affects about 1% of 
couples.3 About half of miscarriages are chro-
mosomally abnormal,4 although this is lower 
in women with recurrent miscarriage.5 It is 
believed that a proportion of the remainder 
are of pregnancies carrying lethal recessive 
genes.6 Despite evidence that some women 
with recurrent miscarriage may have an auto-
immune, thrombotic or endocrine cause; few 
immunologic, antithrombotic or hormone 
therapies have yet been shown to be effective. 
The exception is antiphospholipid syndrome 
(APS), the most important treatable cause 
of recurrent miscarriage, affecting 15-20% 
of women.3 A combination of heparin with 
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Research
strengths and limitations of this study
 ► This is the first time women and those affected 
by miscarriage have worked alongside healthcare 
professionals to prioritise research questions.
 ► In total, 2122 participants prioritised these 
unanswered questions, and 21 key stakeholders 
agreed the top 10 research priorities for miscarriage 
during a final consensus meeting.
 ► Demographic analysis showed similar priorities 
for different ethnicities and agreement between 
healthcare professionals and those affected by 
miscarriage.
 ► Refined questions are broad and may be difficult for 
researchers to interpret.
 ► It is hoped that this top 10 will lead to future research 
that will address issues of importance for the clinical 
management of miscarriage.
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Figure 1 The six-stage process of the miscarriage priority 
setting partnership.
aspirin may be helpful for women with this condition 
, however, the vast majority remain unexplained and 
most women receive no explanation for their miscar-
riage. Despite substantial evidence about the appropriate 
place for medical, surgical and conservative treatment 
for ongoing miscarriage, there remain gaps in our knowl-
edge about how to minimise psychological sequelae.7 
There is also uncertainty about the appropriate inves-
tigation for women who have had particular numbers 
of miscarriages.8 The best way to care for women expe-
riencing miscarriage is uncertain, both when it occurs 
and in subsequent pregnancies.9 Which of these areas of 
research should be a priority? Traditionally, the research 
agenda has been set by the pharmaceutical industry and 
researchers themselves. A large proportion of miscarriage 
research has been funded by charitable trusts, but little 
consideration has been given to the priorities of women 
who have experienced miscarriage, their partners and 
the healthcare professionals (HCPs) who care for them. 
The James Lind Alliance (JLA), established in 2004, is a 
non-profit initiative with the aim of making healthcare 
research funders aware of these issues that matter most to 
patients and clinicians.10 The JLA, whose infrastructure 
is now funded by National Institute of Health Research 
(NIHR), achieves this through priority setting partner-
ships (PSPs), which bring together patients, carers and 
clinicians to identify and prioritise the top 10 uncer-
tainties, or unanswered questions, about the effects of 
treatments.10 The first PSP focused on asthma,11 the NIHR 
have since funded a £1.2 million study into the benefit of 
breathing exercises.12 In women’s health, PSPs have been 
conducted in preterm birth, stillbirth and, most recently, 
endometrial cancer.13–15 We established the miscarriage 
PSP for women, those affected by miscarriage and HCPs 
to collaboratively identify and prioritise important ques-
tions for miscarriage research.
MethODs
Oversight was provided by a steering group listed in 
online supplementary appendix 1 , independently 
chaired by a JLA facilitator (LM), consisting of women 
affected by miscarriage, charities representing them and 
HCPs. The six stages of the PSP are outlined in figure 1 
and follow the PSP process described by the JLA.10 The 
protocol was agreed and published on the JLA website 
before the PSP began (http://www. jla. nihr. ac. uk/ 
priority- setting- partnerships/ miscarriage/). Previous 
JLA PSPs have been reviewed by research ethics commit-
tees and judged as service evaluations, and therefore as 
not requiring research ethics committee review. In view 
of this, in the present case, we followed the practice of 
many recent PSPs14 16–18 and made this decision ourselves 
without formally asking the research ethics committee.
Initiation
Key stakeholder groups were identified through a process 
of peer knowledge and consultation. First, the PSP 
approached all organisations we knew that represented 
the following groups: women who have experienced 
miscarriage; partners, family members, friends or 
colleagues of women who have had a miscarriage; and 
doctors, nurses and professionals allied to medicine with 
clinical experience of treating miscarriage. Organisations 
approached at this stage were the Miscarriage Association, 
Tommy’s, Royal College of Obstetricians and Gynae-
cologists (RCOG) Womens Network, Scottish Care & 
Information on Miscarriage, Fertility Network UK, Hughes 
Syndrome Foundation, Ectopic Pregnancy Trust, Birth-
rights, Mumsnet, Netmums, Babyloss, the Association of 
Early Pregnancy Units, the Royal College of Nursing, the 
British Fertility Society and the Royal College of General 
Practitioners. These organisations were consulted about 
the PSP, invited to participate and identify groups who 
had been excluded, so we could invite them also. Partner 
organisations identified interested individuals to form a 
steering group. The steering group reviewed the partner 
organisations to ensure a broad spectrum of participants 
and to verify that all key stakeholders had been invited to 
be involved. Non-clinical researchers and representatives 
of the pharmaceutical industry were excluded. Steering 
group members completed a declaration of interest form. 
The declaration included declaring: competing interests 
that could be seen to influence participation in the miscar-
riage PSP; any publicly declared strong opinions about 
miscarriage; receipt of any funding that may influence 
your contribution; and involvement in any other activities 
or initiatives that may be seen to influence conduct.
consultation
The steering group was a balanced composition of 
women who had experience of miscarriage, charities 
that represented them and clinicians. Some members 
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representing charities or HCPs also had personal expe-
rience of pregnancy loss. We identified at least four 
conflicting definitions for miscarriage. Most miscarriages 
occur before 12 weeks’ gestation, but the definition of 
early miscarriage varies between organisations. The Euro-
pean Society of Human Reproduction and Embryology 
uses ‘spontaneous pregnancy demise before 10 weeks of 
gestational age’; the RCOG ‘before 10 completed weeks’; 
and the National Institute for Healthcare and Clinical 
Excellence (NICE) ‘before 13 completed weeks’. In the 
UK, the legal definition is spontaneous pregnancy loss 
‘before 24 weeks’ gestation’. Patient representatives high-
lighted that many women would not consider a second 
trimester pregnancy loss to be a miscarriage. Since two 
previous PSPs had ranked research priorities for stillbirth 
and preterm birth, the steering group decided that it was 
unlikely that another PSP would be formed to include late 
miscarriage. Therefore, we chose to define miscarriage as 
anything from a positive pregnancy test to pregnancy loss 
before fetal survival was possible. Threatened miscarriage 
was also included. All aspects of miscarriage including 
conservative, medical and surgical management, psycho-
logical sequelae, treatments for recurrent miscarriage, 
complementary therapies, nutrition and service design 
were included within the scope of the priority setting 
process. Other early pregnancy complications, ectopic 
pregnancy, gestational trophoblastic disease and termina-
tion of pregnancy were excluded.
Identifying questions
An online pilot survey was created consisting of an expla-
nation of what we would like participants to do, guidance 
and example questions. To avoid bias, example questions 
were taken from submissions to other PSPs unrelated to 
women’s health. Participants were simply asked: what 
unanswered questions about miscarriage would you like 
to see answered by research? Each participant could 
complete up to three free text responses. The survey tool 
was peer reviewed by the steering group and piloted by 
eight women and five HCPs. Content validity was ensured 
by this peer review and piloting process. Given the range 
of different constructs measured, internal consistency 
calculations were not undertaken. The feedback received 
was used to rephrase medical language in the description 
and refine the accompanying text for clarity. The refined 
survey was hosted at www. miscarriagepsp. org and distrib-
uted by partner organisations using their own networks; 
promotion in newsletters and conferences; printed flyers 
in clinics; online forums and social media. Participants 
could answer the initial survey anonymously. In addi-
tion to the public survey, we also performed a literature 
search of DARE, the Cochrane Library, RCOG Green 
Top-Guidelines, NICE Guidelines and the HTA Database 
for previously published research questions falling within 
the scope of the PSP.
refining questions
The aim of this stage was to review the questions gathered 
in the identification stage and create a list of summary 
questions. First, we removed non-questions (statements 
or comments) and questions not related to miscarriage 
deemed being out of scope. The remaining questions 
were assigned categories by a single researcher (MP) who 
qualitatively developed a taxonomy based on the focus 
of each uncertainty in turn. For example, ‘Are there any 
ways to protect against miscarriage?’ was assigned to a 
‘prevention’ category. In total, there were 20 categories 
shown in online supplementary appendix 2. Where a 
respondent included more than one uncertainty in the 
same question, we duplicated the response and assigned 
it to each category. Each category was collaboratively 
reviewed by at least one HCP and one patient representa-
tive from the steering group. At this stage, duplicates were 
excluded and questions were combined and rephrased to 
create summary questions, which we refined into a stan-
dard format.10 The full list of summary questions was 
checked and agreed by the steering group. The Cochrane 
Library, MEDLINE, Embase and CINAHL were searched 
from the inception of each until May 2016 for systematic 
reviews of interventions for the management of miscar-
riage. All summary questions were checked against the 
evidence base to determine if they were true questions or 
if the survey respondent was unaware there was already 
evidence to answer their question. If evidence was avail-
able, a link was passed onto the survey respondent so they 
could access it themselves.
Interim prioritisation
The aim of the interim stage was to rank the summary 
questions into those considered important by women 
and those affected by miscarriage and those considered 
important by HCPs. To do this, the refined set of ques-
tions were put into a new online survey and displayed in 
a randomised sequence each time it was accessed. This 
second survey was hosted at www. miscarriagepsp. org 
and participants invited by partner organisations and 
advertised using newsletters, online and social media. 
Participants were asked to read the list of questions and 
identify their 10 priorities. Questions were ranked based 
on the frequency they had been chosen. Participants 
could answer this survey anonymously. Analysis of the 
top priorities for patients and HCPs and women from 
different ethnic origins was performed to ensure the 
overall rankings represented all groups. The top 25 ques-
tions were taken to the final workshop.
Final workshop
Participants were invited to the workshop, representing 
women and partners affected by miscarriage, including 
representatives from charities and HCPs. Prior to the 
meeting, participants completed a declaration of interest 
form and individually prioritised the top 25 questions 
presented in random order labelled A–Y. This allowed 
them to attend the workshop with an idea of their own 
top 10. The workshop was chaired by an independent JLA 
facilitator (KC) with no previous experience of miscar-
riage. Ground rules were agreed at the start of the meeting 
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Figure 2 Flow diagram of process.
to ensure confidentiality of individual’s responses and 
respecting others views and compromise. This process 
intended to prevent the domination of the discussions by a 
single member, encourage quieter members of the group 
to speak and highlight that consensus meant people were 
unlikely to leave the meeting with all their views being 
represented in the final top 10. Participants were divided 
into three groups of mixed representation of women and 
those affected by miscarriage and HCPs. Each group, 
chaired by a JLA facilitator, was asked to prioritise all 25 
questions, which were printed on A4 cards. Each card had 
the interim prioritisation for each group (women and 
those affected by miscarriage and professionals) written 
on the back, to assist with decision making. The three 
sets of rankings were combined into one list. Participants 
were then divided into three different groups, again with 
mixed representation. In the second round, the groups 
were presented with the combined prioritisation from 
round one. Participants were asked to focus on whether 
the correct questions were in the top 10 and had the right 
prioritisation. In the final round, all three groups’ prior-
ities were combined and presented to the entire group. 
The focus was on the top 10. When disagreement arose, 
consensus was reached by raised-hands voting. The top 10 
research priorities in miscarriage were agreed.
Findings
The findings of the miscarriage PSP were reported 
to funding and research agenda setting organisations 
including NIHR Evaluation, Trials and Studies Coordi-
nating Centre, which include the HTA Programme, and 
the Medical Research Council. The findings were also 
reported to Wellbeing of Women and Tommy’s as major 
research funding charities in this field.
results
A flow diagram of the process and results are shown in 
figure 2.
consultation and identifying questions stages
The initial survey was open from 2 November 2015 to 
31 December 2015. Overall, 1093 participants submitted 
3279 questions via the survey and 64 were identified by 
a literature search. Survey respondents included 932 
women who have experienced miscarriage, 8 partners, 
17 family members, friends or colleagues, 104 HCPs and 
8 charitable organisations. Participants were distributed 
according geographical regions as follows: East Midlands: 
84 (8%), East of England: 55 (5%), London: 93 (9%), 
North East: 74 (7%), North West: 126 (12%), Northern 
Ireland: 17 (2%), Scotland: 96 (9%), South East: 147 
(13%), South West: 88 (8%), Wales: 23 (2%), West 
Midlands: 128 (12%), Yorkshire and Humber: 72 (7%), 
outside the UK: 32 (3%) or did not answer: 58 (5%). 
Nine respondents (1%) had threatened, 598 (68%) 
one or two miscarriages, and 274 (31%) had recurrent 
miscarriage. Demographic data for survey respondents 
are shown in online supplementary appendix 3.
refining questions
Submissions that were either non-questions or not 
related to miscarriage were removed and 2402 questions 
remained. Qualitative sorting generated a taxonomy of 
20 categories shown in online supplementary appendix 
2. Each category was assigned to at least one patient 
representative and one clinician from steering group. 
Duplicates were excluded, and submissions were refined 
to 58 summary questions. Referring to the existing liter-
ature, no questions could be resolved at this stage. All 
refined uncertainties are shown in online supplementary 
appendix 4.
Interim prioritisation
The interim prioritisation survey was open between 6 
June 2016 and 1 August 2016 and completed by 2122 
respondents. Respondents were distributed by geograph-
ical regions as follows: East Midlands: 162 (8%), East 
of England: 125 (6%), London: 180 (8%), North East: 
124 (6%), North West: 216 (10%), Northern Ireland: 
54 (3%), Scotland: 218 (10%), South East: 341 (16%), 
South West: 169 (8%), Wales: 65 (3%), West Midlands: 
163 (8%), Yorkshire and Humber: 159 (7%), outside the 
UK: 101 (5%), or did not answer: 45 (2%).
Overall, 1797 women who have experienced miscar-
riage, 22 partners, 68 family members, friends or 
colleagues, 185 HCPs and 31 people whose experience 
of miscarriage was unclear completed the survey. Thir-
teen women with experience of miscarriage (1%) had 
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Table 1 Top 10 ranked research questions for miscarriage
Priority Research question
1 What are the effective interventions to prevent miscarriage, threatened miscarriage and recurrent 
miscarriage? (eg, lifestyle, vitamins, aspirin, early scans, human chorionic gonadotrophin(HCG), dopamine 
agonists, progestogen, polytherapy, steroids, oestrogen, metformin, anticoagulants, intravenous 
immunoglobulin, intralipid and anti-TNF-alpha)
2 What are the emotional and mental health impacts of miscarriage in the short term and long term for the 
mother and the partner?
3 What investigations are of true clinical value? (eg, ultrasound, gene sequencing, natural killer cells, 
thromboelastography, microarray testing of the fetus, paternal investigations, plasminogen activator 
inhibitor polymorphism)
4 To what extent do pre-existing medical conditions cause miscarriage? (eg, vitamin deficiencies, diabetes, 
previous infertility, endometriosis, polycystic ovarian syndrome, menstrual irregularities, cervical factors, 
uterine anomalies, polyps, immunological factors or previous pregnancy complications for example, 
caesarean section or preterm birth)
5 What types of emotional support are effective in preventing or treating women or their partners after a 
miscarriage?
6 Do lifestyle factors (diet, stress, exercise, weight, alcohol, sexual activity, smoking, night shifts or flying) 
cause miscarriage?
7 To what extent do genetic and chromosomal abnormalities in the fetus cause miscarriage?
8 What preconception tests or interventions prevent miscarriage? (eg, vitamin supplements, folic acid, 
dehydroepiandrosterone, co-enzyme Q-10 or bariatric surgery)
9 What are the appropriate investigations for women after one, two, or three or more miscarriages?
10 What male factors contribute towards the cause of miscarriage?
TNF, tumour necrosis factor.
threatened, 1213 (67%) one or two miscarriages, and 
597 (33%) had recurrent miscarriage. The steering 
group recognised the imbalance between those who had 
experienced miscarriage and HCPs. There was also an 
ethnic imbalance (1942 white British/Irish (95%) and 79 
black, Asian and minority ethnic (3.9%) and 18 prefer 
not to say). Considering this, the overall rankings were 
compared with those of each subgroup, lay, HCP, white 
and ethnic minority. The highest 25 overall ranked ques-
tions included the following number of questions from 
each groups top 25: lay: 24, HCP: 18, white: 25 and ethnic 
minority: 21. No uncertainty in the top 8, for HCPs or the 
top 18 for ethnic minorities were excluded from the final 
workshop. This analysis is demonstrated in online supple-
mentary appendix 5. Given this analysis, the steering 
group agreed to take the 25 highest overall ranked ques-
tions to the final workshop.
Final workshop and top 10 priorities
The 1-day workshop took place in October 2016. There 
were 21 participants including 11 women who had experi-
enced miscarriage, 2 male partners of women affected by 
miscarriage and 8 HCPs shown in online supplementary 
appendix 7. The top 10 to research priorities for miscar-
riage were agreed and shown in table 1.
Publicity
Findings were disseminated to funders of miscarriage 
research and shared by partner organisations through 
their own networks. The JLA disseminated the findings 
and publicised descriptive reports of the process itself. 
Finally, the steering group published this academic 
paper.
DIscussIOn
This PSP has established the top 10 research questions for 
miscarriage.
strengths and limitations
To our knowledge, this is the first time where women who 
have experienced and those affected by miscarriage have 
worked together with HCPs to prioritise research ques-
tions. The response to both surveys was comparable with 
other PSPs shown in online supplementary appendix 
6. Nonetheless, as the survey was distributed widely in a 
variety of different media formats, including social media, 
we are unable to assess response rate. Care was taken to 
account for demographic differences between respon-
dents, especially ethnicity and HCPs compared with 
those who had experienced miscarriage. However, no 
data were collected for social status, income and level of 
education that may bias results. Furthermore, this miscar-
riage PSP was predominantly UK based, with only 5% 
of respondents from overseas, making results primarily 
relevant to UK funders and researchers, with relevance to 
other countries uncertain. Collaborative priority setting 
between patients and HCPs is seen as a positive progress 
in research prioritisation, but the optimum proportion 
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Table 2 Comparison with preterm birth and stillbirth PSPs.
Theme Priority
Intervention Miscarriage
  1. What are the effective interventions to prevent miscarriage, threatened miscarriage and recurrent 
miscarriage? (eg, lifestyle, vitamins, aspirin, early scans, HCG, dopamine agonists, progestogen, 
polytherapy, steroids, oestrogen, metformin, anticoagulants, intravenous immunoglobulin, intralipid and 
anti-TNF-alpha)
Preterm birth
  1. Which interventions are most effective to predict or prevent preterm birth?
Stillbirth
  8. Which antenatal care interventions are associated with a reduction in the number of stillbirths?
Support Miscarriage
  2. What are the emotional and mental health impacts of miscarriage in the short term and long term for 
the mother and her partner?
  5. What types of emotional support are effective in preventing or treating women or their partners after a 
miscarriage?
Preterm birth
  5. What should be included in packages of care to support parents and families/carers when a premature 
baby is discharged from hospital?
  9. What emotional and practical support improves attachment and bonding, and does the provision of 
such support improve outcomes for premature babies and their families?
Stillbirth
  7. What is the most appropriate bereavement and postnatal care for both parents following a stillbirth?
  10. How can staff support women and their partners in subsequent pregnancies, using a holistic 
approach, to reduce anxiety, stress and any associated increased visits to healthcare settings?
Lifestyle Miscarriage
  6. Do lifestyle factors (diet, stress, exercise, weight, alcohol, sexual activity, smoking, night shifts or 
flying) cause miscarriage?
Stillbirth
  3. Do modifiable ‘lifestyle’ factors (eg, diet, vitamin deficiency, sleep position, sleep apnoea, lifting and 
bending) cause or contribute to stillbirth risk?
TNF, tumour necrosis factor.
of respondents for each category of participants is not 
known.
The main output of a JLA PSP has traditionally been 
a top 10 list of questions that focus on treatment.10 To 
consider a treatment uncertainty to be answered requires 
an up-to-date systematic review. Recent PSPs, including 
this one, have considered questions broader than treat-
ment questions. This includes questions which, by 
definition, cannot be answered by a systematic review of 
treatments, such as what is the probability of a further 
miscarriage after one, two, three or more previous miscar-
riage(s)? Therefore, none of the 58 summary questions 
could be answered by existing literature. Priorities may 
be skewed towards common conditions. Rarer conditions 
may be diluted due to wide public consultation.
comparison with previous research
Guidelines published by Cochrane, NICE and the RCOG 
have highlighted research gaps. For example, ‘are there 
any lifestyle or personal interventions that can prevent 
miscarriage?’; ‘what types of care are effective in preventing 
mental health problems for mothers and fathers during 
and immediately after a miscarriage?’; and ‘does surgery 
reduce miscarriage in women with uterine anomalies?’. 
Our PSP process has confirmed them as being important 
to women and HCPs. Miscarriage can be considered part 
of the spectrum of poor reproductive outcome ranging 
from subfertility, miscarriage, preterm birth, stillbirth and 
neonatal death. Indeed, some of the potential causes and 
treatments are the same. Comparing our priorities with 
those of the preterm birth13 and stillbirth 14 demonstrated 
some overlap show in table 2. What are the effective inter-
ventions to prevent miscarriage and preterm birth were 
the top priorities and the eighth priority for stillbirth. 
There was desire to see further research into how best 
to provide emotional support to women experiencing all 
three conditions and both the miscarriage and stillbirth 
partnerships prioritised lifestyle factors sixth and third, 
respectively. To complete this spectrum of prioritisation, 
a fertility PSP is required, but we anticipate there will be 
considerable agreement with the priorities of related PSPs.
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clinical implications
Clinicians need to be cognisant of the uncertainty in 
the treatment of miscarriage when counselling women. 
Two priorities in the top 10 are on the emotional well-
being of women and their partners. There has been very 
little good quality research on improving physical and 
emotional health for couples with pregnancy loss.19
research implications
It is reassuring ongoing studies are closely aligned with 
these priorities. Both the NIHR-funded PRISM and 
C-Stitch trials intend to help answer the top priority, inves-
tigating progesterone and cervical cerclage to prevent 
miscarriage, respectively. Nonetheless, many other prior-
ities especially psychological and emotional support 
are less well researched areas. We hope our results will 
encourage both researchers and funders to focus on these 
priorities. Some questions cover broad topics, overlap with 
other questions or do not translate easily into questions 
research studies can be designed to answer. We intend 
to work closely with NIHR to refine these priorities into 
research questions with involvement from patients and 
professionals. Nonetheless, future research must be high 
quality as simply adding more poorly quality studies will 
not provide answers to these important questions. Study 
design must be appropriate to the research question and 
follow EQUATOR guidelines for publication.
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